{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:34Z","timestamp":1789684894895,"version":"4.0.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine and Surgery"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.amsu.2021.102980","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T15:19:51Z","timestamp":1635607191000},"page":"102980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review"],"prefix":"10.1097","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-3900","authenticated-orcid":false,"given":"Yousef S.","family":"Abuzneid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-3101","authenticated-orcid":false,"given":"Hussam I.A.","family":"Alzeerelhouseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Marzouqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2745-4910","authenticated-orcid":false,"given":"Yasmine","family":"Yaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa R.","family":"Al-Ihribat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Alqam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Krama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"17","key":"10.1016\/j.amsu.2021.102980_bib1","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amsu.2021.102980_bib2","first-page":"100172","article-title":"Atypical chronic myeloid leukemia BCR-ABL 1 negative: a case report and literature review","volume":"12","author":"Belkhair","year":"2019","journal-title":"Leuk Res Rep"},{"issue":"5","key":"10.1016\/j.amsu.2021.102980_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"Suppl 1","key":"10.1016\/j.amsu.2021.102980_bib4","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S2152-2650(20)30477-8","article-title":"Update on CML-like disorders","volume":"20","author":"Cross","year":"2020","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"2","key":"10.1016\/j.amsu.2021.102980_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MOH.0000000000000565","article-title":"Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms","volume":"27","author":"Sadigh","year":"2020","journal-title":"Curr. Opin. Hematol."},{"issue":"18","key":"10.1016\/j.amsu.2021.102980_bib6","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.3390\/ijms21186862","article-title":"Atypical chronic myeloid leukemia: where are we now?","volume":"21","author":"Cris\u00e0","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.amsu.2021.102980_bib7","article-title":"Atypical chronic myeloid leukemia","author":"Levinson","year":"2018","journal-title":"BCR\/ABL1 Negative"},{"key":"10.1016\/j.amsu.2021.102980_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.amsu.2021.102980_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720927105","article-title":"A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: a case report and literature review","volume":"11","author":"Gao","year":"2020","journal-title":"Ther. Adv. Hematol."},{"issue":"8","key":"10.1016\/j.amsu.2021.102980_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.amsu.2021.102980_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"issue":"35","key":"10.1016\/j.amsu.2021.102980_bib12","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.amsu.2021.102980_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/leu.2013.337","article-title":"The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases","volume":"28","author":"Solary","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.amsu.2021.102980_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.amsu.2021.102980_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11899-011-0108-8","article-title":"Role of TET2 mutations in myeloproliferative neoplasms","volume":"7","author":"Pronier","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"12","key":"10.1016\/j.amsu.2021.102980_bib16","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.amsu.2021.102980_bib17","first-page":"218","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"JClinEpi"},{"issue":"4","key":"10.1016\/j.amsu.2021.102980_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/ijc.IJC_506_18","article-title":"Atypical chronic myeloid leukemia achieving good response with azacitidine","volume":"56","author":"Marumo","year":"2019","journal-title":"Indian J. Cancer"}],"container-title":["Annals of Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080121009304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080121009304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:09:27Z","timestamp":1677082167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2049080121009304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":18,"alternative-id":["S2049080121009304"],"URL":"https:\/\/doi.org\/10.1016\/j.amsu.2021.102980","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Annals of Medicine and Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amsu.2021.102980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102980"}}